han fanghai

Prof. Dr. han fanghai


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LZLin Zhong
Lin Zhong
BYBin Yang
Bin Yang
ZZZhenhua Zhang
Zhenhua Zhang
JWJunfeng Wang
Junfeng Wang
XWXiaojuan Wang
Xiaojuan Wang
JWJunjian Wang
Junjian Wang
Advanced gastric cancer (GCa) remains highly lethal due to the lack of effective therapies. Identifying promising therapeutic targets and developing effective treatment against GCa are urgently needed. Through mRNA and protein analysis of GCa clinical tumor samples, we found that autophagy-related gene 4B (ATG4B) was overexpressed in GCa tumors and that its high expression was associated with patients’ poor prognosis. Knockdown of ATG4B significantly inhibited GCa cell survival and tumor growth. To further probe the role of ATG4B in GCa by pharmacological means, we screened an in-house marine natural compound library against ATG4B and identified Azalomycin F4a (Am-F4a) as a novel and potent ATG4B inhibitor. Am-F4a directly bound to ATG4B with high affinity and effectively suppressed GCa cell autophagy via inhibition of ATG4B both in vitro and in vivo. Moreover, Am-F4a or ATG4B knockdown significantly suppressed tumor growth as well as GCa cell migration and invasion. Am-F4a effectively blocked the metastatic progression of primary GCa and sensitized tumors to chemotherapy. Taken together, our findings indicate that ATG4B is a potential therapeutic target against GCa and the natural product Am-F4a is a novel ATG4B inhibitor that can be further developed for the treatment of GCa.

1 November 2019 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
JTJianan Tan
Jianan Tan
BYBin YANG
Bin YANG
ZXZhimeng Xu
Zhimeng Xu
SZShengning Zhou
Shengning Zhou
ZCZhitao Chen
Zhitao Chen
HFhan fanghai
han fanghai
Background: The prognostic value of tumor deposit (TD) in gastric cancer is controversial. This study aims to investigate the prognostic value of TD. Methods: The consecutive patients diagnosed with gastric cancer from October 2007 to October 2012 were selected. The patients were divided by whether they suffered TD into two groups. The basic data were comparable between the two groups after propensity score matching (PSM), then survival analysis [overall survival (OS) and cancer-specific survival (CSS)] was applied in two groups. After that, all the patients were divided by pN staging and survival analysis were applied in each subgroup. At last, all patients were divided into TD group, pN1 stage group, pN2 stage group, pN3a, and pN3b stage group, OS and CSS were compared between them. Multivariable competing risk analyses tested association of TD with OS and CSS, before and after PSM. Results: Eight hundred and three patients were concluded. After PSM, 137 patients with TD and 274 patients without TD were selected, the 5-year OS and CSS rates of patients with TD were significantly worse than patients without TD (OS: 19.7% vs. 42.0%, P<0.001; CSS: 22.6% vs. 45.6%, P<0.001). In all patients’ survival analysis, the 5-year OS and CSS rates of TD group were comparable with pN3a group (OS: 19.7% vs. 25.3%, P=0.221, CSS: 22.6% vs. 30.1%, P=0.092) and pN3b group (OS: 19.7% vs. 19.6% P=0.349, CSS: 22.6% vs. 23.5%, P=0.452). Meanwhile, on multivariable cox regression analyses, the presence of TD significantly reduces the OS and CSS of patients in gastric cancer. Conclusions: TD has a marked impact on the prognosis of gastric cancer. Even patients with TD had the same prognosis with pN3 stage.

1 July 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
SMShuai Ma
Shuai Ma
YHYiwei Hu
Yiwei Hu
JCJianjiao Chen
Jianjiao Chen
XWXiaojuan Wang
Xiaojuan Wang
CZChenxi Zhang
Chenxi Zhang
JWJunfeng Wang
Junfeng Wang

3 November 2023 in Translational Oncology
Verified
Journal Article
Open access
JYJin-Hao Yu
Jin-Hao Yu
JTJia-Nan Tan
Jia-Nan Tan
GZGuang-Yu Zhong
Guang-Yu Zhong
LZLin Zhong
Lin Zhong
DHDong Hou
Dong Hou
HFhan fanghai
han fanghai
Circular RNAs (circRNAs) are a distinct class of non-coding RNAs that play regulatory roles in the initiation and progression of tumors. With advancements in transcriptome sequencing technology, numerous circRNAs that play significant roles in tumor-related genes have been identified. In this study, we used transcriptome sequencing to analyze the expression levels of circRNAs in normal adjacent tissues, primary colorectal cancer (CRC) tissues, and CRC tissues with liver metastasis. We successfully identified the circRNA hsa_circ_0020134 (circ0020134), which exhibited significantly elevated expression specifically in CRC with liver metastasis. Importantly, high levels of circ0020134 were associated with a poor prognosis among patients. Functional experiments demonstrated that circ0020134 promotes the proliferation and metastasis of CRC cells both in vitro and in vivo. Mechanistically, upregulation of circ0020134 was induced by the transcription factor, PAX5, while miR-183-5p acted as a sponge for circ0020134, leading to partial upregulation of PFN2 mRNA and protein levels, thereby further activating the downstream TGF-β/Smad pathway. Additionally, downregulation of circ0020134 inhibited epithelial-mesenchymal transition (EMT) in CRC cells, which could be reversed by miR-183-5p inhibitor treatment. Collectively, our findings confirm that the circ0020134-miR-183-5p-PFN2-TGF-β/Smad axis induces EMT transformation within tumor cells, promoting CRC proliferation and metastasis, thus highlighting its potential as a therapeutic target for patients with CRC liver metastasis.

18 May 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
XGXumeng Gong
Xumeng Gong
DHDong Hou
Dong Hou
SZShengning Zhou
Shengning Zhou
JTJianan Tan
Jianan Tan
GZGuangyu Zhong
Guangyu Zhong
LZLin Zhong
Lin Zhong
Objective: To explore the relationship between flavin-containing monooxygenases (FMOs) and peritoneal metastasis (PM) in gastric cancer (GC).Materials and methods: TIMER 2.0 was used to perform pan-cancer analysis and assess the correlation between the expression of FMOs and cancers. A dataset from The Cancer Genome Atlas (TCGA) was used to analyze the correlation between FMOs and clinicopathological features of GC. PM is well established as the most common mode of metastasis in GC. To further analyze the correlation between FMOs and PM of GC, a dataset was obtained from the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database. The results were validated by immunohistochemistry. The relationship between FMOs and PM of GC was explored, and a novel PM risk signature was constructed by least absolute shrinkage and selection operator (LASSO) regression analysis. The regression model’s validity was tested by multisampling. A nomogram was established based on the model for predicting PM in GC patients. The mechanism of FMOs in GC patients presenting with PM was assessed by conducting Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses in TCGA and GEO datasets. Finally, the potential relationship between FMOs and immunotherapy was analyzed.Results: The pan-cancer analysis in TCGA and GEO datasets showed that FMO1 was upregulated, while FMO2 and FMO4 were downregulated in GC. Moreover, FMO1 and FMO2 correlated positively with the T and N stage of GC in the TCGA dataset. FMO1 and FMO2 expression was a risk factor for GC (hazard ratio: 1.112 and 1.185). The overexpression of FMO1 was significantly correlated with worse disease-free-survival (DFS) and overall survival (OS). However, no relationship was found between FMO2 expression in GC and DFS and OS. PM was highly prevalent among GC patients and typically associated with a worse prognosis. FMO1 was highly expressed in GC with PM. FMO1 and FMO2 were positively correlated with PM in GC. We identified a 12-gene panel for predicting the PM risk signature by LASSO (Area Under Curve (AUC) = 0.948, 95%CI: 0.896–1.000). A 10-gene panel for PM prediction was identified (AUC = 0.932, 95%CI: 0.874–0.990), comprising FMO1 and FMO2. To establish a model for clinical application, a 7-gene panel was established (AUC = 0.927, 95% CI: 0.877–0.977) and successfully validated by multisampling. (AUC = 0.892, 95% CI: 0.878–0.906). GO and KEGG analyses suggest that FMO1 and FMO2 regulate the extracellular matrix and cell adhesion. FMO1 and FMO2 were positively correlated with the immune score of GC, and their expression was associated with the infiltration of immune cells.Conclusion: PM in GC is strongly correlated with FMOs. Overall, FMO1 and FMO2 have huge prospects for application as novel diagnostic and therapeutic targets.

22 January 2025 in Heliyon
Verified
Journal Article
Open access
LGLong Gui
Long Gui
JYJin-Hao Yu
Jin-Hao Yu
JTJia-Nan Tan
Jia-Nan Tan
GZGuang-Yu Zhong
Guang-Yu Zhong
YWYong-Xue Wang
Yong-Xue Wang
SZSheng-Ning Zhou
Sheng-Ning Zhou
Carbohydrate sulfotransferase (CHST) is a Golgi membrane-associated enzyme with potential as a cancer diagnostic marker. In this study, we obtained the transcriptional profile and corresponding clinical information of CHST1 in gastric cancer (GC) tissues and normal tissues from The Cancer Genome Atlas database. Our functional experiments have demonstrated that CHST1 enhances the proliferation and metastasis of GC cells, both in vitro and in vivo. Furthermore, we constructed a co-expression network of CHST1 and explored its relationship with clinicopathological features, the tumor microenvironment, and immune infiltration through bioinformatics analysis. Finally, relevant drugs that inhibit CHST1 in GC were predicted using the drug susceptibility database (CellMiner) and Cancer Immunome Atlas. Overall, CHST1 may serve as a promising prognostic biomarker for GC, as it is linked to immune infiltration and facilitates GC cell proliferation and metastasis.